- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02858830
Familial Partial Lipodystrophy Study (FPL)
Genetic and Metabolic Basis of Familial Partial Lipodystrophy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A systematic study of body fat distribution is necessary to better define the phenotypic spectrum of FPL, and to better recognize FPL in patients with Metabolic Syndrome. Similarly, genetic studies in these patients will not only help better characterize the genotype-phenotype relationship, but is also likely to help identify other genes involved in regulation of lipid homeostasis, as some patients may not have any of the known mutations.
The Investigators will systematically study mitochondrial protein quality and function under fasting and fed state in relation to intramyocellular and circulating plasma lipid levels, and compare with age, sex and BMI-matched individuals. The Investigators will also study the rate of de-novo protein synthesis to determine if hyperinsulinemia affects both muscle protein anabolism and catabolism.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of lipodystrophy (decreased subcutaneous fat)
- Family history of lipodystrophy
- Normal control subject
Exclusion Criteria:
- Inability to provide informed consent
- Hemoglobin < 10g%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Group 1: Healthy Subject
Healthy Subject (Control) will undergo assessments before and after ingesting a high fat mixed meal.
|
|
|
Other: Group 2: FPL Subject
FPL Subject will undergo assessments before and after ingesting a high fat mixed meal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Upper body muscle strength measured by chest press dynamometry
Time Frame: Before consumption of a high fat mixed meal
|
Before consumption of a high fat mixed meal
|
|
Change in fractional mitochondrial protein synthesis rates
Time Frame: Before and after consumption of a high fat mixed meal (approximately 4 hours after the meal)
|
Before and after consumption of a high fat mixed meal (approximately 4 hours after the meal)
|
|
Lower body muscle strength measured by knee extension
Time Frame: Before consumption of a high fat mixed meal
|
Before consumption of a high fat mixed meal
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vinaya Simha, MBBS, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-009144
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lipodystrophy, Familial Partial
-
University Hospital, LilleCompletedFamilial Partial Lipodystrophy Type 2France
-
Akcea TherapeuticsIonis Pharmaceuticals, Inc.TerminatedFamilial Partial LipodystrophyUnited States, Netherlands, Belgium, Brazil, Canada, Germany, Russian Federation
-
Abhimanyu GargCompletedFamilial Partial LipodystrophyUnited States
-
Amryt PharmaRecruitingFamilial Partial LipodystrophyUnited States
-
Akcea TherapeuticsIonis Pharmaceuticals, Inc.CompletedFamilial Partial LipodystrophyUnited States
-
Cambridge University Hospitals NHS Foundation TrustRecruitingDiabetes | Diet Modification | LipodystrophyUnited Kingdom
-
University of MichiganAvailable
-
Regeneron PharmaceuticalsTerminatedFamilial Partial Lipodystrophy | Metabolic AbnormalitiesUnited States, France, Spain, Turkey (Türkiye)
-
University of MichiganCompletedNAFLD | Nonalcoholic Steatohepatitis | Familial Partial LipodystrophyUnited States
-
Elif OralCompletedFatty Liver | Hypertriglyceridemia | NASH - Nonalcoholic Steatohepatitis | Familial Partial LipodystrophyUnited States
Clinical Trials on High fat mixed meal
-
Instituto de Investigacion Sanitaria La FeHospital Universitario La Fe; Universitat Politècnica de ValènciaNot yet recruitingType 1 Diabetes Mellitus | Menstrual Cycle | Dietary Fat | Glycemic Variability | Postprandial Glucose | Sex CharacteristicsSpain
-
University of AarhusDanish Diabetes AcademyCompletedType 2 Diabetes | NAFLDDenmark
-
USDA, Western Human Nutrition Research CenterTerminatedObesity | Overweight | Body WeightUnited States
-
Agroscope Liebefeld-Posieux Research Station ALPCompletedObesity | Nutritional InterventionSwitzerland
-
Pennington Biomedical Research CenterCompletedDiabetes Mellitus, Type 2United States
-
Hospital Universitari Vall d'Hebron Research InstituteCompleted
-
Universidad IcesiUniversidad de San BuenaventuraCompletedCardiovascular DiseasesColombia
-
Ball State UniversityRecruiting
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingObesity | type1diabetesUnited States
-
Wageningen UniversityTop Institute Food and NutritionCompletedCardiovascular Disease | Endothelial DysfunctionNetherlands